Edition:
United Kingdom

Fujifilm Holdings Corp (4901.T)

4901.T on Tokyo Stock Exchange

4,566JPY
7:00am BST
Change (% chg)

¥-26 (-0.57%)
Prev Close
¥4,592
Open
¥4,568
Day's High
¥4,605
Day's Low
¥4,543
Volume
1,308,100
Avg. Vol
1,313,531
52-wk High
¥5,618
52-wk Low
¥4,025

About

FUJIFILM Holdings Corporation is a Japan-based holding company engaged in the business related to photography, medical care & printing & liquid crystal display materials and copying machines. The Company operates in three business segments. Imaging Solutions segment develops, manufactures and sells color films, digital cameras,... (more)

Overall

Beta: 0.77
Market Cap(Mil.): ¥2,760,967.00
Shares Outstanding(Mil.): 514.63
Dividend: 47.50
Yield (%): 1.49

Financials

  4901.T Industry Sector
P/E (TTM): 16.44 14.68 15.87
EPS (TTM): 326.29 -- --
ROI: 6.13 6.38 14.17
ROE: 6.71 8.09 15.63

Japan's Fujifilm buys biologics unit from Biogen to boost healthcare business

TOKYO Japan's Fujifilm Holdings Corp will buy a drugmaking business from U.S.-based Biogen Inc for about $890 million (674.8 million pounds) to try to bolster its healthcare business as growth at its legacy photocopy operations stagnates.

12 Mar 2019

Japan's Fujifilm buys biologics unit from Biogen to boost healthcare business

TOKYO Japan's Fujifilm Holdings Corp will buy a drugmaking business from U.S.-based Biogen Inc for about $890 million to try to bolster its healthcare business as growth at its legacy photocopy operations stagnates.

12 Mar 2019

UPDATE 2-Japan's Fujifilm buys biologics unit from Biogen to boost healthcare business

* Fujifilm expects 100 bln yen revenue from CDMO business by 2021 (Adds details and background)

12 Mar 2019

Fujifilm says to buy Biogen's subsidiary for around $890 mln

TOKYO, March 12 Fujifilm Holdings Corp said on Tuesday it is buying a subsidiary of Biogen Inc , Biogen Denmark Manufacturing ApS, for around $890 million to bolster its healthcare business.

12 Mar 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates